LYSINE BIOTECH PRIVATE LIMITED
Product development and Manufacture of drugs, biomarkers and vaccines from Protein and DNA
CIN:U74999TN2018PTC122879
| S.No | LYSINE BIOTECH Small molecules based drugs delivery (IND) | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB101 Kilirag-1 drug for treating type 2 diabetes in obese | 2026 | ||
| 2 | LB102 Ktictide-NPPA Congestive Heart Failure (IND) | 2026 | ||
| 3 | LB103 Kpondin1 (Spondin-1)- Alzheimer's (IND) | 2026 |
| S.No | LYSINE BIOTECH Cell Therapy pipelines 2nd, 3rd & 4th generation of CART Cell, MSCs and Dentritic cells Therapy | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB201 Novel human anti-Cd19CART-CD27/4-1BB-CD3Z targeting CD19 | 2026 | ||
| 2 | LB202 Novel human anti-Cd20CART-CD27/4-1BB-CD3Z targeting CD20 | 2027 | ||
| 3 | LB203 Novel human anti-GD2CART-CD27/4-1BB-CD3Z targeting glioblastoma (GBM), sarcomas, and neuroblastoma, express high levels of the tumor-associated antigens GD2. | 2027 | ||
| 4 | LB204 Novel human anti-BCMACART-CD27/4-1BB-CD3Z targeting Multiple Myeloma BCMA | 2027 | ||
| 5 | LB205 Novel human anti-FAPCART-CD27/NFAT-CD3Z targeting Cardiac fibrosis | 2027 | ||
| 6 | LB206 Novel human Allogenic Cd5CART-CD27/4-1BB-CD3Z targeting Antigen | 2027 | ||
| 7 | LB207 Novel human Allogenic Neoantigen p53CART-CD27/4-1BB-CD3Z targeting Antigen & Solid tumors | 2027 | ||
| 9 | LB209 Novel human Allogenic Neoantigen p53 Dentritic cells-CD27/4-1BB/NFAT-CD3Z targeting Solid tumors | 2027 | ||
| 8 | LB208 Novel human bi-cistronic anti-GPRC5D-hCD3CART-CD27/CD28/4-1BB/NFAT-CD3Z targeting Multiple Myeloma | 2027 | ||
| 10 | LB210 Novel human bi-cistronic hMSCs-anti-hGD2hCART-CD27/4-1BB/NFAT-CD3Z targeting glioblastoma (GBM), sarcomas, and neuroblastoma, express high levels of the tumor-associated antigens GD2 | 2027 | ||
| 11 | LB211 Novel human bi-cistronic anti-Cd19-20CART-CD27/CD28/4-1BB/NFAT-CD3Z targeting CD19-CD20-CD22 | 2027 | ||
| 12 | LB212 Novel human tri-cistronic anti-Cd19-20-22CART-CD27/CD28/4-1BB/NFAT-CD3Z targeting CD19-CD20-CD22 | 2027 |
| S.No | LYSINE BIOTECH AAV1-10 human mRNA based Gene therapy | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB301 AAV-DMD gene therapy designed to deliver a copy of the mRNA encoding the human DMD | 2028 | ||
| 2 | LB302 AAV-FGFR2 gene therapy designed to deliver a copy of the mRNA encoding the human FGFR2 | 2028 | ||
| 3 | LB303 AAV-SMN1 gene therapy designed to deliver a copy of the mRNA encoding the human SMN1 | 2028 | ||
| 4 | LB304 AAV-FVIII gene therapy designed to deliver a copy of the mRNA encoding the humanFVIII | 2028 | ||
| 5 | LB305 AAV-RPE65 gene therapy designed to deliver a copy of the mRNA encoding the human RPE65 | 2028 | ||
| 6 | LBP306 AAV-BCL11A gene therapy designed to deliver a copy of the mRNA encoding the human BCL11A | 2028 | ||
| 7 | LBP307 AAV-BCL6A gene therapy designed to deliver a copy of the mRNA encoding the human BCL6A | 2028 | ||
| 8 | LBP308 AAV-COL7A1 gene therapy designed to deliver a copy of the mRNA encoding the human COL7A1 | 2028 | ||
| 9 | LB309 AAV-FIX gene therapy designed to deliver a copy of the mRNA encoding the human FIX | 2028 | ||
| 10 | LB310 AAV-HBB gene therapy designed to deliver a copy of the mRNA encoding the human HBB | 2028 | ||
| 11 | LB311 AAV-DDC gene therapy designed to deliver a copy of the mRNA encoding the human DDC | 2028 | ||
| 12 | LB312 AAV-TIMP2 gene therapy designed to deliver a copy of the mRNA encoding the human TIMP2 | 2028 | ||
| 13 | LB313 AAV-BAG3 gene therapy designed to deliver a copy of the mRNA encoding the human BAG3 | 2028 | ||
| 14 | LB314 AAV-TTN gene therapy designed to deliver a copy of the mRNA encoding human TTN elastic protein plays a crucial role in muscle contraction(skeletal & cardiac),and relaxation | 2028 |
| S.No | LYSINE BIOTECH Biobetters mAbs Pipeline | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB401 Kenralizumab (Benralizumab) | 2029 | ||
| 2 | LB402 Kaplacizumb (Caplacizumab) | 2029 | ||
| 3 | LB403 Kurvalumab (Durvalumab) | 2029 | ||
| 4 | LBPL404 Kemiplimab (Cemiplimab) | 2029 | ||
| 5 | LB405 Kbalizumab (Ibalizumab) | 2029 | ||
| 6 | LB406 Koxetumomab pasudodox (Moxetumomab pasudodox) | 2029 | ||
| 7 | LB407 Komosozumab (Romosozumab) | 2029 | ||
| 8 | LB408 Kisankizumab (Risankizumab) | 2029 | ||
| 9 | LB409 Krolucizumab (Brolucizumab) | 2029 | ||
| 10 | LB410 Krizanlizumab (Crizanlizumab) | 2028 |
| S.No | LYSINE BIOTECH LNP based mRNA delivery for Vaccine and therapeutics | Discovery stage and Early process development | Preclinical | Clinical trials |
| 1 | LB501 mRNA vaccine four in one Dengue 1-4 | 2029 | ||
| 2 | LB502 mRNA Chikungunya vaccine | 2029 | ||
| 3 | LB503 mRNA Sporozoite & Circumsporozoite vaccine (malaria) | 2029 | ||
| 4 | LB504 mRNA monkeypox vaccine | 2029 | ||
| 5 | LB505 mRNA Horsepox vaccine | 2029 | ||
| 6 | LB506 mRNA Buffalopox vaccine | 2029 | ||
| 7 | LB507 mRNA Vaccinia vaccine | 2029 | ||
| 8 | LB508 LNP based mRNA veterinary vaccine against African swine fever virus | 2029 | ||
| 9 | LB509 LNP based mRNA human and veterinary vaccine against Rabies virus (GLYCO_RABVP) | 2028 | ||
| 10 | LB510 mRNA FMD vaccine (unique India) | 2028 | ||
| 11 | LB511 LNP based mRNA human and veterinary vaccine against leptospirosis | 2029 | ||
| 12 | LB512 mRNA LYSKrouzon FGFR2 protein therapeutics | 2027 |